ORS 443.454: Provision of opioid overdose reversal medication upon discharge, release or transfer of resident from facility where resident received addiction treatment.

(1) As used in this section, “facility” means a residential care facility, residential treatment facility or residential treatment home licensed under ORS 443.410. (2) Notwithstanding ORS 689.800, upon the discharge or release of a resident, a facility shall provide to the resident at least two doses of an opioid overdose reversal medication and the necessary medical supplies to administer the medication if: (a) The resident received addiction treatment at the facility for a current opioid use disorder; and (b) The resident is discharged, released or transferred to an unlicensed private residence or other unlicensed setting. (3)(a) Except as provided in paragraph (b) of this subsection, a person who is acting in good faith, if the act does not constitute wanton misconduct, is immune from civil liability for any act or omission of an act committed during the course of providing to a resident opioid overdose reversal medications, and the necessary medical supplies to administer the medications, under subsection (2) of this section. (b) This subsection does not apply to a person involved in the manufacture or sale of opioid overdose reversal medication. (4) The requirements of subsection (2) of this section do not apply if a resident leaves the facility against the facility’s advice. [2023 c.297 §6] Sec. 7. The Oregon Health Authority shall facilitate access to opioid overdose reversal medications and the necessary medical supplies to administer the medications for hospitals licensed under ORS chapter 441, long term care facilities as defined in ORS 442.015, facilities as defined in section 4 of this 2023 Act [430.263] and facilities as defined in section 6 of this 2023 Act [443.454] for the purposes of carrying out sections 2 [441.052], 3 [441.698], 4 and 6 of this 2023 Act. [2023 c.297 §7]